WO2011028800A3 - Treatment of cognitive dysfunction with gangliosides - Google Patents

Treatment of cognitive dysfunction with gangliosides Download PDF

Info

Publication number
WO2011028800A3
WO2011028800A3 PCT/US2010/047528 US2010047528W WO2011028800A3 WO 2011028800 A3 WO2011028800 A3 WO 2011028800A3 US 2010047528 W US2010047528 W US 2010047528W WO 2011028800 A3 WO2011028800 A3 WO 2011028800A3
Authority
WO
WIPO (PCT)
Prior art keywords
gangliosides
cognitive dysfunction
treatment
patient
administering
Prior art date
Application number
PCT/US2010/047528
Other languages
French (fr)
Other versions
WO2011028800A2 (en
Inventor
Jay S. Schneider
Gerri Henwood
Robert Florentine
Original Assignee
Lazarus Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lazarus Therapeutics, Inc. filed Critical Lazarus Therapeutics, Inc.
Publication of WO2011028800A2 publication Critical patent/WO2011028800A2/en
Publication of WO2011028800A3 publication Critical patent/WO2011028800A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

A method of treating or preventing cognitive dysfunction in a human patient in need thereof comprising administering one or more gangliosides to said patient, wherein said patient is undergoing chemotherapy or irradiation treatment for cancer.
PCT/US2010/047528 2009-09-01 2010-09-01 Treatment of cognitive dysfunction with gangliosides WO2011028800A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12373509A 2009-09-01 2009-09-01
US6123735 2009-09-01

Publications (2)

Publication Number Publication Date
WO2011028800A2 WO2011028800A2 (en) 2011-03-10
WO2011028800A3 true WO2011028800A3 (en) 2011-07-07

Family

ID=43649945

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/047528 WO2011028800A2 (en) 2009-09-01 2010-09-01 Treatment of cognitive dysfunction with gangliosides

Country Status (1)

Country Link
WO (1) WO2011028800A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210353659A1 (en) * 2018-08-24 2021-11-18 Industry-Academic Cooperation Foundation, Yonsei University Composition for preventing or treating muscular diseases, or for improving muscular functions, containing gagnlioside

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080064709A1 (en) * 2006-09-11 2008-03-13 Duke University Methods and compositions for the treatment of vascular depression

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080064709A1 (en) * 2006-09-11 2008-03-13 Duke University Methods and compositions for the treatment of vascular depression

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FRANCO DI GREGORIO ET AL.: "Efficacy of ganglioside treatment in reducing functional alterations induced by vincristine in rabbit peripheral nerves.", CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol. 26, no. 1, 1990, pages 31 - 36 *
PAMELA NEW: "Radiation injury to the nervous system.", CURRENT OPINION IN NEUROLOGY, vol. 14, no. 6, 2001, pages 725 - 734 *
TOSHIO ARIGA ET AL.: "Role of ganglioside metabolism in the pathogenesis of Alzheimer's disease-a review.", JOURNAL OF LIPID RESEARCH, vol. 49, no. 6, 2008, pages 1157 - 1175 *

Also Published As

Publication number Publication date
WO2011028800A2 (en) 2011-03-10

Similar Documents

Publication Publication Date Title
MX2010012860A (en) Methods of treating cancer of the central nervous system.
WO2012002760A3 (en) Method for treating and diagnosing cancer by using cell-derived microvesicles
MX363243B (en) Compositions and methods for treating cancer.
MX2013012253A (en) Novel binder-drug conjugates (adcs) and their use.
MX2019005130A (en) Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin.
NZ701715A (en) Means and methods for treating dlbcl
PH12014501880A1 (en) Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy
MX2014000777A (en) Catheter, particularly an indwelling catheter, for treating functional problems and/or diseases of the bladder and/or prostate.
NZ719520A (en) Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
MX365688B (en) Drug delivery systems and methods for treatment of bladder cancer comprising oxaliplatin.
MX367070B (en) Drug delivery systems and methods for treatment of prostate disease comprising gemicitabine.
SG10201810575WA (en) Treatment of prostate cancer with tor kinase inhibitors
WO2013096335A8 (en) ADMINISTRATION OF AN ANTAGONIST OF α5β1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT
WO2012037008A3 (en) Therapy for mll-rearranged leukemia
MX2007001206A (en) Methods of treating skin to enhance therapeutic treatment thereof.
WO2011133826A3 (en) Method for treating pancreatic cancer
WO2010117992A3 (en) Coupled identification and treatment of cancer
CR20110687A (en) PROCEDURES FOR USE OF CORTICOTROPINE RELEASE FACTOR FOR CANCER TREATMENT
WO2011028800A3 (en) Treatment of cognitive dysfunction with gangliosides
WO2011133827A3 (en) Method of treating prostate cancer
WO2011072181A3 (en) Method of treating pancreatic cancer
WO2010124239A3 (en) Genetic polymorphisms associated with clinical outcomes of topoisomerase inhibitor therapy for cancer
WO2012012304A3 (en) Method of treating refractory cancer
WO2011139867A3 (en) Method of treating brain cancer
WO2012075210A3 (en) Method for treating refractory cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10814426

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10814426

Country of ref document: EP

Kind code of ref document: A2